This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Enhancement of Postocclusive Reactive Hyperaemia by Dipyridamole

This study has been completed.
Information provided by:
Radboud University Identifier:
First received: December 21, 2005
Last updated: March 27, 2008
Last verified: March 2008
The purpose of this study is to determine whether dipyridamole enhances postocclusive reactive hyperaemia by increasing extracellular adenosine concentrations during ischemia and reperfusion. Furthermore we hypothesize that dipyridamole augments postocclusive reactive hyperaemia by increasing adenosine receptor stimulation.

Condition Intervention
Hyperemia Hypoxia Drug: dipyridamole Drug: caffeine

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: Enhancement of Postocclusive Reactive Hyperaemia

Resource links provided by NLM:

Further study details as provided by Radboud University:

Primary Outcome Measures:
  • forearm blood flow

Estimated Enrollment: 12
Study Start Date: December 2005
Study Completion Date: July 2006

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • healthy volunteers between 18 and 50 years

Exclusion Criteria:

  • none specified
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00268554

Radboud university Nijmegen Medical Centre
Nijmegen, Gelderland, Netherlands, 6533 ZA
Sponsors and Collaborators
Radboud University
Principal Investigator: Gerard Rongen, MD,PhD Radboud University
  More Information Identifier: NCT00268554     History of Changes
Other Study ID Numbers: PORH-dipy
Study First Received: December 21, 2005
Last Updated: March 27, 2008

Keywords provided by Radboud University:

Additional relevant MeSH terms:
Vascular Diseases
Cardiovascular Diseases
Central Nervous System Stimulants
Physiological Effects of Drugs
Phosphodiesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Purinergic P1 Receptor Antagonists
Purinergic Antagonists
Purinergic Agents
Neurotransmitter Agents
Platelet Aggregation Inhibitors
Vasodilator Agents processed this record on September 21, 2017